Heatwurx (PCSA) to Release Quarterly Earnings on Wednesday

Heatwurx (NASDAQ:PCSA) will likely be posting its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Heatwurx to post earnings of ($0.08) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 3:30 PM ET.

Heatwurx (NASDAQ:PCSA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). On average, analysts expect Heatwurx to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Heatwurx Price Performance

Shares of Heatwurx stock opened at $0.31 on Tuesday. Heatwurx has a 1-year low of $0.15 and a 1-year high of $1.50. The company has a market capitalization of $15.66 million, a PE ratio of -0.13 and a beta of 1.53. The business has a 50-day moving average of $0.25 and a 200-day moving average of $0.25.

Analyst Ratings Changes

A number of brokerages have weighed in on PCSA. HC Wainwright lowered their price objective on Heatwurx from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, September 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research note on Wednesday, October 8th. Finally, Zacks Research lowered shares of Heatwurx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $1.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.